{
"info": {
"nct_id": "NCT00064129",
"official_title": "A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer",
"inclusion_criteria": "* Histologically confirmed prostate cancer\n\n * Metastatic disease\n* Progressive disease after prior androgen deprivation as defined by at least 1 of the following criteria:\n\n * Patients with measurable disease must have an increase of at least 20% in the sum of the longest diameter of target lesions OR the appearance of 1 or more new lesions\n * Patients with nonmeasurable disease must have a positive bone scan and a prostate-specific antigen (PSA) level of at least 5 ng/mL, which has risen on at least 2 successive occasions at least 2 weeks apart*\n\n * At least 1 PSA level must be obtained at least 4 weeks after flutamide (6 weeks after bicalutamide or nilutamide)\n* Testosterone no greater than 50 ng/dL\n\n * Patients with no prior orchiectomy must continue luteinizing hormone-releasing hormone agonist therapy\n* No history or radiologic evidence of CNS metastases\n* Performance status - ECOG 0-2\n* At least 12 weeks\n* Absolute neutrophil count greater than 1,500/mm^3\n* Platelet count at least 100,000/mm^3\n* Hemoglobin at least 8 g/dL\n* Bilirubin less than 1.5 times upper limit of normal (ULN)\n* SGOT and SGPT no greater than 2.5 times ULN\n* Creatinine no greater than 1.5 times ULN\n* No significant cardiovascular disease\n* No New York Heart Association class III or IV congestive heart failure\n* No active angina pectoris\n* No myocardial infarction within the past 6 months\n* Not pregnant or nursing\n* Fertile patients must use effective contraception prior to, during, and for 3 months after study participation\n* No history of autoimmune disease including, but not limited to, any of the following:\n\n * Autoimmune hemolytic anemia\n * Ulcerative and hemorrhagic colitis\n * Endocrine disorders (e.g., thyroiditis, hyperthyroidism, hypothyroidism of immune etiology, autoimmune hypophysitis/hypopituitarism, or adrenal insufficiency)\n * Sarcoid granuloma\n * Myasthenia gravis\n * Polymyositis\n * Guillain-Barre syndrome\n * Systemic lupus erythematosus\n * Rheumatoid arthritis\n * Inflammatory bowel disease\n* No other medical or psychiatric illness that would preclude study participation or giving informed consent\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission\n* No prior immunotherapy (e.g., vaccines or investigational)\n* No other concurrent colony-stimulating factors\n* No prior chemotherapy\n* No concurrent chemotherapy\n* See Disease Characteristics\n* At least 4 weeks since prior systemic corticosteroids\n* At least 4 weeks since other prior hormonal therapy, including megestrol and finasteride\n* No concurrent systemic steroid therapy except inhaled or topical steroids\n* No other concurrent hormonal therapy\n\n * Hormones administered for nondisease-related conditions (e.g., insulin for diabetes) allowed\n* At least 4 weeks since prior radiotherapy and recovered\n* More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 and samarium Sm 153 lexidronam pentasodium)\n* Prior irradiation of a symptomatic lesion or one that may produce disability (e.g., unstable femur) allowed\n* No concurrent palliative radiotherapy\n* See Disease Characteristics\n* At least 4 weeks since prior herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically confirmed prostate cancer",
"criterions": [
{
"exact_snippets": "Histologically confirmed prostate cancer",
"criterion": "prostate cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically confirmed"
}
]
}
]
},
{
"line": "* Metastatic disease",
"criterions": [
{
"exact_snippets": "Metastatic disease",
"criterion": "metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Progressive disease after prior androgen deprivation as defined by at least 1 of the following criteria:",
"criterions": [
{
"exact_snippets": "Progressive disease after prior androgen deprivation",
"criterion": "progressive disease after androgen deprivation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with measurable disease must have an increase of at least 20% in the sum of the longest diameter of target lesions OR the appearance of 1 or more new lesions",
"criterions": [
{
"exact_snippets": "measurable disease",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "increase of at least 20% in the sum of the longest diameter of target lesions",
"criterion": "increase in sum of longest diameter of target lesions",
"requirements": [
{
"requirement_type": "percentage increase",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "%"
}
}
]
},
{
"exact_snippets": "appearance of 1 or more new lesions",
"criterion": "new lesions",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesions"
}
}
]
}
]
},
{
"line": "* At least 1 PSA level must be obtained at least 4 weeks after flutamide (6 weeks after bicalutamide or nilutamide)",
"criterions": [
{
"exact_snippets": "At least 1 PSA level must be obtained",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "at least 4 weeks after flutamide",
"criterion": "time since flutamide",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "6 weeks after bicalutamide or nilutamide",
"criterion": "time since bicalutamide or nilutamide",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Testosterone no greater than 50 ng/dL",
"criterions": [
{
"exact_snippets": "Testosterone no greater than 50 ng/dL",
"criterion": "testosterone level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 50,
"unit": "ng/dL"
}
}
]
}
]
},
{
"line": "* Patients with no prior orchiectomy must continue luteinizing hormone-releasing hormone agonist therapy",
"criterions": [
{
"exact_snippets": "no prior orchiectomy",
"criterion": "prior orchiectomy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "must continue luteinizing hormone-releasing hormone agonist therapy",
"criterion": "luteinizing hormone-releasing hormone agonist therapy",
"requirements": [
{
"requirement_type": "continuation",
"expected_value": true
}
]
}
]
},
{
"line": "* No history or radiologic evidence of CNS metastases",
"criterions": [
{
"exact_snippets": "No history ... of CNS metastases",
"criterion": "CNS metastases",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "No ... radiologic evidence of CNS metastases",
"criterion": "CNS metastases",
"requirements": [
{
"requirement_type": "radiologic evidence",
"expected_value": false
}
]
}
]
},
{
"line": "* Performance status - ECOG 0-2",
"criterions": [
{
"exact_snippets": "Performance status - ECOG 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "ECOG"
},
{
"operator": "<=",
"value": 2,
"unit": "ECOG"
}
]
}
}
]
}
]
},
{
"line": "* At least 12 weeks",
"criterions": [
{
"exact_snippets": "At least 12 weeks",
"criterion": "duration",
"requirements": [
{
"requirement_type": "minimum duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Absolute neutrophil count greater than 1,500/mm^3",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count greater than 1,500/mm^3",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 1500,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Platelet count at least 100,000/mm^3",
"criterions": [
{
"exact_snippets": "Platelet count at least 100,000/mm^3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm^3"
}
}
]
}
]
},
{
"line": "* Hemoglobin at least 8 g/dL",
"criterions": [
{
"exact_snippets": "Hemoglobin at least 8 g/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 8,
"unit": "g/dL"
}
}
]
}
]
},
{
"line": "* Bilirubin less than 1.5 times upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": "Bilirubin less than 1.5 times upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 1.5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* SGOT and SGPT no greater than 2.5 times ULN",
"criterions": [
{
"exact_snippets": "SGOT ... no greater than 2.5 times ULN",
"criterion": "SGOT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "SGPT no greater than 2.5 times ULN",
"criterion": "SGPT",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* Creatinine no greater than 1.5 times ULN",
"criterions": [
{
"exact_snippets": "Creatinine no greater than 1.5 times ULN",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times ULN"
}
}
]
}
]
},
{
"line": "* No significant cardiovascular disease",
"criterions": [
{
"exact_snippets": "No significant cardiovascular disease",
"criterion": "cardiovascular disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "not significant"
}
]
}
]
},
{
"line": "* No New York Heart Association class III or IV congestive heart failure",
"criterions": [
{
"exact_snippets": "No New York Heart Association class III or IV congestive heart failure",
"criterion": "New York Heart Association class",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "!=",
"value": 3,
"unit": "class"
}
},
{
"requirement_type": "severity",
"expected_value": {
"operator": "!=",
"value": 4,
"unit": "class"
}
}
]
}
]
},
{
"line": "* No active angina pectoris",
"criterions": [
{
"exact_snippets": "No active angina pectoris",
"criterion": "angina pectoris",
"requirements": [
{
"requirement_type": "activity",
"expected_value": false
}
]
}
]
},
{
"line": "* No myocardial infarction within the past 6 months",
"criterions": [
{
"exact_snippets": "No myocardial infarction within the past 6 months",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "time since last event",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Fertile patients must use effective contraception prior to, during, and for 3 months after study participation",
"criterions": [
{
"exact_snippets": "Fertile patients",
"criterion": "fertility",
"requirements": [
{
"requirement_type": "status",
"expected_value": "fertile"
}
]
},
{
"exact_snippets": "must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
},
{
"exact_snippets": "prior to, during, and for 3 months after study participation",
"criterion": "contraception use duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": "prior to, during, and for 3 months after study participation"
}
]
}
]
},
{
"line": "* No history of autoimmune disease including, but not limited to, any of the following:",
"criterions": [
{
"exact_snippets": "No history of autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
},
{
"line": "* Autoimmune hemolytic anemia",
"criterions": [
{
"exact_snippets": "Autoimmune hemolytic anemia",
"criterion": "autoimmune hemolytic anemia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Ulcerative and hemorrhagic colitis",
"criterions": [
{
"exact_snippets": "Ulcerative ... colitis",
"criterion": "ulcerative colitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "hemorrhagic colitis",
"criterion": "hemorrhagic colitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Endocrine disorders (e.g., thyroiditis, hyperthyroidism, hypothyroidism of immune etiology, autoimmune hypophysitis/hypopituitarism, or adrenal insufficiency)",
"criterions": [
{
"exact_snippets": "Endocrine disorders (e.g., thyroiditis",
"criterion": "thyroiditis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Endocrine disorders (e.g., ... hyperthyroidism",
"criterion": "hyperthyroidism",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Endocrine disorders (e.g., ... hypothyroidism of immune etiology",
"criterion": "hypothyroidism of immune etiology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Endocrine disorders (e.g., ... autoimmune hypophysitis/hypopituitarism",
"criterion": "autoimmune hypophysitis/hypopituitarism",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Endocrine disorders (e.g., ... adrenal insufficiency",
"criterion": "adrenal insufficiency",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Sarcoid granuloma",
"criterions": [
{
"exact_snippets": "Sarcoid granuloma",
"criterion": "sarcoid granuloma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Myasthenia gravis",
"criterions": [
{
"exact_snippets": "Myasthenia gravis",
"criterion": "myasthenia gravis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Polymyositis",
"criterions": [
{
"exact_snippets": "Polymyositis",
"criterion": "polymyositis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Guillain-Barre syndrome",
"criterions": [
{
"exact_snippets": "Guillain-Barre syndrome",
"criterion": "Guillain-Barre syndrome",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Systemic lupus erythematosus",
"criterions": [
{
"exact_snippets": "Systemic lupus erythematosus",
"criterion": "systemic lupus erythematosus",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Rheumatoid arthritis",
"criterions": [
{
"exact_snippets": "Rheumatoid arthritis",
"criterion": "rheumatoid arthritis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Inflammatory bowel disease",
"criterions": [
{
"exact_snippets": "Inflammatory bowel disease",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* No other medical or psychiatric illness that would preclude study participation or giving informed consent",
"criterions": [
{
"exact_snippets": "No other medical ... illness that would preclude study participation",
"criterion": "medical illness",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other ... psychiatric illness that would preclude study participation",
"criterion": "psychiatric illness",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other medical or psychiatric illness that would preclude ... giving informed consent",
"criterion": "ability to give informed consent",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or stage I or II cancer currently in complete remission",
"criterions": [
{
"exact_snippets": "No other malignancy within the past 5 years",
"criterion": "other malignancy",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
},
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "except adequately treated basal cell or squamous cell skin cancer",
"criterion": "basal cell or squamous cell skin cancer",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "adequately treated"
}
]
},
{
"exact_snippets": "except ... stage I or II cancer currently in complete remission",
"criterion": "stage I or II cancer",
"requirements": [
{
"requirement_type": "remission status",
"expected_value": "complete remission"
}
]
}
]
},
{
"line": "* No prior immunotherapy (e.g., vaccines or investigational)",
"criterions": [
{
"exact_snippets": "No prior immunotherapy",
"criterion": "prior immunotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "(e.g., vaccines or investigational)",
"criterion": "type of immunotherapy",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"vaccines",
"investigational"
]
}
]
}
]
},
{
"line": "* No other concurrent colony-stimulating factors",
"criterions": [
{
"exact_snippets": "No other concurrent colony-stimulating factors",
"criterion": "colony-stimulating factors",
"requirements": [
{
"requirement_type": "concurrent use",
"expected_value": false
}
]
}
]
},
{
"line": "* No prior chemotherapy",
"criterions": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No concurrent chemotherapy",
"criterions": [
{
"exact_snippets": "No concurrent chemotherapy",
"criterion": "concurrent chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* See Disease Characteristics",
"criterions": [
{
"exact_snippets": "Disease Characteristics",
"criterion": "disease characteristics",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "see details"
}
]
}
]
},
{
"line": "* At least 4 weeks since prior systemic corticosteroids",
"criterions": [
{
"exact_snippets": "At least 4 weeks since prior systemic corticosteroids",
"criterion": "systemic corticosteroids",
"requirements": [
{
"requirement_type": "time since last use",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* At least 4 weeks since other prior hormonal therapy, including megestrol and finasteride",
"criterions": [
{
"exact_snippets": "At least 4 weeks since other prior hormonal therapy",
"criterion": "time since prior hormonal therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "including megestrol and finasteride",
"criterion": "prior hormonal therapy drugs",
"requirements": [
{
"requirement_type": "specific drugs",
"expected_value": [
"megestrol",
"finasteride"
]
}
]
}
]
},
{
"line": "* No concurrent systemic steroid therapy except inhaled or topical steroids",
"criterions": [
{
"exact_snippets": "No concurrent systemic steroid therapy",
"criterion": "systemic steroid therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "except inhaled or topical steroids",
"criterion": "inhaled or topical steroids",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* No other concurrent hormonal therapy",
"criterions": [
{
"exact_snippets": "No other concurrent hormonal therapy",
"criterion": "concurrent hormonal therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Hormones administered for nondisease-related conditions (e.g., insulin for diabetes) allowed",
"criterions": [
{
"exact_snippets": "Hormones administered for nondisease-related conditions (e.g., insulin for diabetes) allowed",
"criterion": "hormone administration",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "nondisease-related"
}
]
}
]
},
{
"line": "* At least 4 weeks since prior radiotherapy and recovered",
"criterions": [
{
"exact_snippets": "At least 4 weeks since prior radiotherapy",
"criterion": "time since prior radiotherapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "recovered",
"criterion": "recovery from prior radiotherapy",
"requirements": [
{
"requirement_type": "status",
"expected_value": "recovered"
}
]
}
]
},
{
"line": "* More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 and samarium Sm 153 lexidronam pentasodium)",
"criterions": [
{
"exact_snippets": "More than 8 weeks since prior radiopharmaceuticals",
"criterion": "time since prior radiopharmaceuticals",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">",
"value": 8,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Prior irradiation of a symptomatic lesion or one that may produce disability (e.g., unstable femur) allowed",
"criterions": [
{
"exact_snippets": "Prior irradiation of a symptomatic lesion",
"criterion": "prior irradiation of symptomatic lesion",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "one that may produce disability",
"criterion": "lesion that may produce disability",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
}
]
},
{
"line": "* No concurrent palliative radiotherapy",
"criterions": [
{
"exact_snippets": "No concurrent palliative radiotherapy",
"criterion": "palliative radiotherapy",
"requirements": [
{
"requirement_type": "concurrency",
"expected_value": false
}
]
}
]
},
{
"line": "* See Disease Characteristics",
"criterions": [
{
"exact_snippets": "Disease Characteristics",
"criterion": "disease characteristics",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "see details"
}
]
}
]
},
{
"line": "* At least 4 weeks since prior herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto)",
"criterions": [
{
"exact_snippets": "At least 4 weeks since prior herbal products known to decrease PSA levels",
"criterion": "time since prior herbal products",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "herbal products known to decrease PSA levels (e.g., PC-SPES or saw palmetto)",
"criterion": "herbal products known to decrease PSA levels",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "* Patients with nonmeasurable disease must have a positive bone scan and a prostate-specific antigen (PSA) level of at least 5 ng/mL, which has risen on at least 2 successive occasions at least 2 weeks apart*",
"criterions": [
{
"exact_snippets": "nonmeasurable disease",
"criterion": "disease measurability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "positive bone scan",
"criterion": "bone scan result",
"requirements": [
{
"requirement_type": "result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "prostate-specific antigen (PSA) level of at least 5 ng/mL",
"criterion": "PSA level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "ng/mL"
}
}
]
},
{
"exact_snippets": "PSA level ... has risen on at least 2 successive occasions at least 2 weeks apart",
"criterion": "PSA level rise",
"requirements": [
{
"requirement_type": "frequency",
"expected_value": true
}
]
}
]
},
{
"line": "* Not pregnant or nursing",
"criterions": [
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "not ... nursing",
"criterion": "nursing status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
}
]
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}